Impact of Statin Use on Immunotherapy Outcomes and Efficacy in Non-Small Cell Lung Cancer Patients

International Journal of Molecular Sciences 2026 Open access

Read full text
Authors: A. Yakobson, Abed Agbarya, Yulia Dudnik, Itamar Gothelf, Asmah Miari, Ronen Brenner, Ashraf Abu Jama, Nashat Abu Yasin, Abd El Nazer Dabah, Amichay Meirovitz, Natalie Maimon Rabinovich, Walid Shalata
DOI: 10.3390/ijms27031541
Cited by: 3
References: 41

Abstract

Immune checkpoint inhibitors (ICIs) have improved outcomes in advanced non-small cell lung cancer (NSCLC). The influence of statin use, chemotherapy, PD-L1 expression, and sex on immunotherapy outcomes remains incompletely defined in real-world settings. We performed a multicenter retrospective analysis of patients with advanced NSCLC treated with immunotherapy-based regimens. Patients were stratified by statin exposure, chemotherapy use, PD-L1 expression (

Fields of Study & Subjects

Cancer Lipids and Metabolism Cancer Immunotherapy and Biomarkers Ferroptosis and cancer prognosis

Publication details

Journal / source
International Journal of Molecular Sciences
Publisher
MDPI AG
Volume
27
Issue
3
Pages
1541–1541
Publication date
4 February 2026
Language
EN